The abstract is read at the publisher; the summary is JClub's.
Small molecules that bind STRAD’s nucleotide pocket stabilize the LKB1-STRAD-MO25 complex, activating wild-type LKB1 and reducing tumor cell growth.
- Why it matters: Loss-of-function mutations in STK11/LKB1 are linked to poor prognosis and therapy resistance, yet they are difficult to drug directly.
- What they did: Kretschmer and colleagues used small-molecule binding to STRAD’s nucleotide pocket to stabilize the LKB1-STRAD-MO25 complex and trigger downstream tumor-suppressor signaling.
- The result: The stabilized complex activates wild-type LKB1 and downstream signaling, which is linked to reduced growth of tumor cells and suggests a STRAD-targeting strategy.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.